TG Therapeutics Inc (TGTX)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Also measured against its sector ETF (XBI).
Our last 30 days of resolved calls came true 18% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- Weekly momentum+7.9% over the past week+6
- 12-month trend+108% over the past year+10
- 52-week positionPressing 52-week highs+30
- QualityRevenue growing 76% y/y+10
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is earnings, specifically the raised revenue guidance and the debate over whether the stock's valuation is justified. Continuation likelihood over the next few weeks is moderate (roughly 40–50%), since guidance-driven moves often fade as valuation concerns resurface without fresh fundamental news. Informational only — not financial advice.
- TG Therapeutics: 3 Key Takeaways for Long-Term InvestorsYahoo · 2026-11-15
- Stock Market Rebounds Even As Nvidia CEO Jensen Huang Resigns, Treasury Yields Jump: Weekly ReviewYahoo · 2026-11-13
- The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and MadrigalYahoo · 2026-11-11
- TG Therapeutics (TGTX) Lifts Revenue Guidance As Investors Ask If The Stock Is PriceyYahoo · 2026-11-11
- TG Therapeutics (TGTX) Stock Stays Hard To Justify Despite Raised Revenue GuidanceYahoo · 2026-11-11
Any AI summary is an interpretation of public news, not advice or a price target.